Neuroprotective activity of selenium nanoparticles against the effect of amino acid enantiomers in Alzheimer’s disease

Vicente-Zurdo, David; Rodríguez-Blázquez, Sandra; Gómez-Mejía, Esther; Rosales-Conrado, Noelia; León-González, María Eugenia; Madrid, Yolanda

doi:10.1007/s00216-022-04285-z

Cited by 11 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipids (e.g., gangliosides and cholesterol) and divalent metal ions (e.g., zinc, copper, and iron) are good nucleators for Aβ ( Section 2.4 ) [ 45 ]. Experiments (TEM studies of Aβ aggregates) demonstrated that several D-amino acids (D-Ala, D-Phe, D-Glu, and D-Asp) and DL-selenoMet initiate Aβ aggregation (enantiomeric-induced aggregation [ 46 ]). Most of the L-amino acids did not affect amyloid aggregation.…”

Section: Alzheimer’s Diseasementioning

confidence: 99%

See 1 more Smart Citation

New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer’s Disease

Penke

Szücs

Bogár³

2023

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is an incurable, progressive neurodegenerative disorder. AD is a complex and multifactorial disease that is responsible for 60–80% of dementia cases. Aging, genetic factors, and epigenetic changes are the main risk factors for AD. Two aggregation-prone proteins play a decisive role in AD pathogenesis: β-amyloid (Aβ) and hyperphosphorylated tau (pTau). Both of them form deposits and diffusible toxic aggregates in the brain. These proteins are the biomarkers of AD. Different hypotheses have tried to explain AD pathogenesis and served as platforms for AD drug research. Experiments demonstrated that both Aβ and pTau might start neurodegenerative processes and are necessary for cognitive decline. The two pathologies act in synergy. Inhibition of the formation of toxic Aβ and pTau aggregates has been an old drug target. Recently, successful Aβ clearance by monoclonal antibodies has raised new hopes for AD treatments if the disease is detected at early stages. More recently, novel targets, e.g., improvements in amyloid clearance from the brain, application of small heat shock proteins (Hsps), modulation of chronic neuroinflammation by different receptor ligands, modulation of microglial phagocytosis, and increase in myelination have been revealed in AD research.

show abstract

Section: Alzheimer’s Diseasementioning

confidence: 99%

“…The novel combination has good absorption and might improve resveratrol application in AD treatment [ 127 ]. Chitosan-containing selenium nanoparticles (Ch-SeNPs) also inhibited D-amino acid enantiomeric-induced amyloid aggregation [ 46 ].…”

Section: Conventional and Novel Targets For Slowing And/or Preventing...mentioning

confidence: 99%

New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer’s Disease

Penke

Szücs

Bogár³

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…The enantiomer-induced Aβ42 aggregation was carried out as described previously. 48 Amyloid fibrils formed were placed onto a clean silicon wafer and were assessed by FESEM.…”

Section: Studying the Disaggregation Propensity Of Rδf-senps Towards ...mentioning

confidence: 99%

Anti-amyloidogenic amphipathic arginine-dehydrophenylalanine spheres capped selenium nanoparticles as potent therapeutic moieties for Alzheimer's disease

et al. 2023

View full text Add to dashboard Cite

show abstract

“…effects, such as Se NPs coated with Tet-1 peptide and stabilized by the epigallocatechin-3-gallate (EGCG) (Tet-1-EGCG@Se), [179] the polyvinyl alcohol (PVA)-coated SeNPs (PVA-SeNPs), [180] the chitosan-coated Se NPs (ChSeNPs), [181] the quercetin-loaded Se NPs (P80-Que@SeNPs), [182] and the selenium nanoparticles stabilized with chitosan (Ch-SeNPs) (Table 1). [183] Furthermore, another Se NPs coated with dihydromyricetin (DMY) (Tg-CS/DMY@SeNPs) (Table 1) ameliorate neuroinflammation through the gut microbiota-NLRP3 inflammasome-brain axis in APP/PS1 mice. [184] Chiral l/d-Fe x Cu y Se NPs ( D -Fe x Cu y Se NPs) (Figure 4) [185] produce a mass of ROS and effectively lower the stability of folding conformation of A𝛽1-42 fibrils or stop the monomer fibrillation under 808nm NIR illumination which reduces cytotoxicity.…”

Section: Se Nanoparticles (Se Nps)mentioning

confidence: 99%

“…Other Se NPs also exhibited similar therapeutic effects, such as Se NPs coated with Tet‐1 peptide and stabilized by the epigallocatechin‐3‐gallate (EGCG) (Tet‐1‐EGCG@Se), [ 179 ] the polyvinyl alcohol (PVA)‐coated SeNPs (PVA‐SeNPs), [ 180 ] the chitosan‐coated Se NPs (ChSeNPs), [ 181 ] the quercetin‐loaded Se NPs (P80‐Que@SeNPs), [ 182 ] and the selenium nanoparticles stabilized with chitosan (Ch‐SeNPs) (Table 1). [ 183 ] Furthermore, another Se NPs coated with dihydromyricetin (DMY) (Tg‐CS/DMY@SeNPs) (Table 1) ameliorate neuroinflammation through the gut microbiota‐NLRP3 inflammasome‐brain axis in APP/PS1 mice. [ 184 ]…”

Section: Low‐dimensional Nanomaterials For Alzheimer's Disease Treatmentmentioning

confidence: 99%

Alzheimer's Disease: Status of Low‐Dimensional Nanotherapeutic Materials

Huang,

Liao,

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a chronic progressive neurodegenerative disease that constitutes the third most common cause of death among elderly individuals. AD patients suffer from behavioral problems regularly, like memory loss, thinking deficits, and cognitive disorders. Currently, the incidence rate of AD has been on the rise worldwide. Therefore, it is imperative to develop effective strategies for the treatment and prevention of AD. The inherent characteristics of low‐dimensional nanomaterials, primarily their smaller size and surface structure, make them well‐suited for fulfilling the essential requirements of therapeutic drug design. Consequently, these nanomaterials offer a highly appealing and alternative approach to treating AD. Here, the low‐dimensional nanomaterials used in the treatment of AD to provide new ideas, methods, and comprehensive perspectives for the management of AD are reviewed. This review will advance the comprehensive understanding of the potential of low‐dimensional nanomaterials in the field of neuro medicine, which also will have a positive impact on future research.

show abstract

Neuroprotective activity of selenium nanoparticles against the effect of amino acid enantiomers in Alzheimer’s disease

Cited by 11 publications

References 42 publications

New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer’s Disease

New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer’s Disease

Anti-amyloidogenic amphipathic arginine-dehydrophenylalanine spheres capped selenium nanoparticles as potent therapeutic moieties for Alzheimer's disease

Alzheimer's Disease: Status of Low‐Dimensional Nanotherapeutic Materials

Contact Info

Product

Resources

About